OKYO Pharma Ltd is a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases... Show more
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| BKT | 9.65 | 0.04 | +0.42% |
| BlackRock Income Trust | |||
| SLTY | 19.06 | -0.24 | -1.24% |
| YieldMax Ultra Short Option Income Strategy ETF (SLTY) | |||
| CHIQ | 15.55 | -0.24 | -1.54% |
| Global X MSCI China Consumer Discretionary ETF (CHIQ) | |||
| REMX | 51.60 | -1.77 | -3.32% |
| VanEck Rare Earth and Strategic Metals ETF (REMX) | |||
| EVMU | 27.57 | -2.78 | -9.17% |
| Direxion Daily Ether Bull 2X ETF (EVMU) | |||
A.I.dvisor tells us that OKYO and XRTX have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that OKYO and XRTX's prices will move in lockstep.
| Ticker / NAME | Correlation To OKYO | 1D Price Change % | ||
|---|---|---|---|---|
| OKYO | 100% | +12.41% | ||
| XRTX - OKYO | 30% Poorly correlated | -2.66% | ||
| RXRX - OKYO | 30% Poorly correlated | -0.55% | ||
| BEAM - OKYO | 29% Poorly correlated | -0.36% | ||
| HYFT - OKYO | 28% Poorly correlated | -1.55% | ||
| OCGN - OKYO | 28% Poorly correlated | +0.32% | ||
More | ||||
Industry Biotechnology
OKYO broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 36 similar instances where the stock broke above the upper band. In 33 of the 36 cases the stock fell afterwards. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OKYO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for OKYO entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where OKYO's RSI Indicator exited the oversold zone, 9 of 15 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 60%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 37 of 46 cases where OKYO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on OKYO as a result. In 72 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for OKYO just turned positive on October 01, 2026. Looking at past instances where OKYO's MACD turned positive, the stock continued to rise in 30 of 37 cases over the following month. The odds of a continued upward trend are 81%.
OKYO moved above its 50-day moving average on October 21, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +13.95% 3-day Advance, the price is estimated to grow further. Considering data from situations where OKYO advanced for three days, in 128 of 149 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. OKYO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 50 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 60 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (20.951) is normal, around the industry mean (2.973). P/E Ratio (-3.944) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.